Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now, we re going to talk about a really interesting set of presentations at San Antonio that I think really do have direct implications for clinical practice on Monday and this is the use of genomic tests and in some of the studies, Ki67 in order to try and inform us about how to treat our patients who have higher risk node-positive disease.
Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now I think what we ll do is focus on novel therapy, some of the novel therapies that were presented at San Antonio. We can t be exhaustive, of course, but we ll talk about some of the agents that either are already being used in the clinic or are emerging agents. One area of great interest is oral taxanes. We ve been trying to get oral taxanes for ages. There is a problem with absorpti
MedCity News
Trial results add to uses for Exact Sciences test
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy and those who won t. The latest trial results extend the test s reach.
Shares1
A clinical trial shows that a genomic test from diagnostics company Exact Sciences can help more women with early-stage breast cancer avoid chemotherapy.
The test, Oncotype DX, had already demonstrated its ability to predict whether chemotherapy would benefit women with breast cancer that has not spread to lymph nodes, known as node-negative breast cancer.
Following is a transcript of their remarks:
Rugo: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now at San Antonio this year we saw an update of the really interesting monarchE data, the adjuvant trial looking at abemaciclib versus not additional therapy combined with endocrine therapy in the adjuvant setting for 2 years in patients who have quite high-risk early-stage hormone receptor-positive, HER2-negative breast cancer.